Search results
News about COVID-19, William Schaffner (professor), FLiRT
News about COVID-19, Pfizer, absenteeism
Also in the news
1 day ago · Boosters that target the omicron subvariants of SARS-CoV-2 are still providing reasonably durable protection against infection, hospitalization and death from COVID-19, according to new data from ...
1 day ago · A COVID-19 antigen rapid test. A new variant of COVID-19, known as FLiRT, is now the most dominant strain in the U.S. This variant, which evolved from the omicron strain, is characterized by changes in its spike protein — the part of the virus that binds to host cells.
2 days ago · On September 11, 2023, the updated Moderna and Pfizer–BioNTech mRNA vaccines (i.e., 2023–2024 formulas) against coronavirus disease 2019 (Covid-19) containing the severe acute respiratory ...
1 day ago · The current COVID-19 boosters targeting the Omicron XBB.1.5 subvariant are still offering solid protection against infection, hospitalizations, and death, but are somewhat limited in efficacy against illnesses caused by the JN.1 subvariant, now the dominant strain in the United States, according to a research letter yesterday in the New England ...
2 days ago · Published today in the New England Journal of Medicine, the study found that COVID-19 boosters targeting the XBB.1.5 subvariants were most effective one month after receiving one. After four weeks ...
2 days ago · May 29, 2024 New research led by Dr. Danyu Lin finds that boosters targeting omicron subvariants of SARS-CoV-2 are still providing reasonably durable protection against infection, hospitalization and death from COVID-19, but they are less protective against the now-dominant JN.1 strain.
2 days ago · The updated monovalent XBB.1.5 COVID-19 vaccines were effective against Omicron subvariants circulating during the most recent respiratory virus season, but their effectiveness waned over time ...
